SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, announced today that the company's
President and CEO Theodore Schroeder will present the company's corporate
overview at the following investment conferences:
-- Deutsche Bank's 33rd Annual Healthcare Conference at the
InterContinental Hotel in Boston on Tuesday, May 6, 2008 at 2:10pm
Eastern Time (11:10am Pacific Time)
-- Bank of America's 2008 Healthcare Conference at the Four Seasons Hotel
in Las Vegas on Wednesday, May 14, 2008 at 4:00pm Pacific Time (7:00pm
-- JMP Securities' Seventh Annual Research Conference at the Ritz-Carlton
Hotel in San Francisco on Wednesday, May 21, 2008 at 12:00pm Pacific
Time (3:00pm Eastern Time)
Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentations, click on the Investor Relations tab the link entitled "Events and Presentations" on the left side of the screen. A replay of each webcast will available approximately one hour after the live webcast concludes and will remain available for 30 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.
Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals,
Contacts: William R. LaRue Anna Gralinska
SVP & Chief Financial Officer Director, Investor Relations
Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.
858-436-1400 (858) 436-1452
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved